Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
Ovarian cancer
breast cancer gene (BRCA)
homologous recombination (HR)
poly(ADP-ribose) polymerase inhibitors (PARP inhibitors)
talazoparib
veliparib
Journal
Annals of translational medicine
ISSN: 2305-5839
Titre abrégé: Ann Transl Med
Pays: China
ID NLM: 101617978
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
entrez:
25
1
2021
pubmed:
26
1
2021
medline:
26
1
2021
Statut:
ppublish
Résumé
Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer mortality among women, potentially due to ineffectiveness of screening tests for early detection. Patients typically present with advanced disease at diagnosis, whereas, up to 80% relapse and the estimated median progression-free survival (PFS) is approximately 12-18 months. Increased knowledge on the molecular biology of EOC resulted in the development of several targeted therapies, including poly(ADP-ribose) polymerase (PARP) inhibitors. These agents have changed the therapeutic approach of the EOC and exploit homologous recombination (HR) deficiency through synthetic lethality, especially in breast cancer genes 1 and 2 (
Identifiants
pubmed: 33490218
doi: 10.21037/atm.2020.03.156
pii: atm-08-24-1706
pmc: PMC7812175
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1706Informations de copyright
2020 Annals of Translational Medicine. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm.2020.03.156). The series “Ovarian Cancer: State of the Art and Perspectives of Clinical Research” was commissioned by the editorial office without any funding or sponsorship. SB and NP served as the unpaid Guest Editors of the series. The other authors have no conflicts of interest to declare.
Références
Oncotarget. 2017 Jan 24;8(4):6057-6066
pubmed: 28002809
Int J Gynecol Cancer. 2017 Nov;27(9):1842-1849
pubmed: 28763368
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Nat Rev Genet. 2008 Aug;9(8):619-31
pubmed: 18626472
Gynecol Oncol. 2018 Mar;148(3):507-514
pubmed: 29352572
N Engl J Med. 2012 Apr 12;366(15):1382-92
pubmed: 22452356
Gynecol Oncol. 2017 Nov;147(2):267-275
pubmed: 28882436
Cancer Res. 2011 Sep 1;71(17):5626-34
pubmed: 21795476
Clin Cancer Res. 2010 Sep 15;16(18):4527-31
pubmed: 20823148
Clin Cancer Res. 2009 Dec 1;15(23):7277-90
pubmed: 19934293
Nat Rev Genet. 2017 Oct;18(10):613-623
pubmed: 28649135
Oncotarget. 2017 Jul 25;8(30):48794-48806
pubmed: 27447864
Clin Cancer Res. 2013 Sep 15;19(18):5003-15
pubmed: 23881923
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
Clin Cancer Res. 2007 May 1;13(9):2728-37
pubmed: 17473206
Lancet Oncol. 2019 May;20(5):636-648
pubmed: 30948273
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
Invest New Drugs. 2020 Feb;38(1):181-193
pubmed: 31650446
Clin Cancer Res. 2015 Jan 1;21(1):68-76
pubmed: 25355929
J Transl Med. 2016 Sep 15;14:267
pubmed: 27634150
Diagnostics (Basel). 2019 May 18;9(2):
pubmed: 31109041
Nature. 2005 Apr 14;434(7035):913-7
pubmed: 15829966
Clin Cancer Res. 2012 Mar 15;18(6):1726-34
pubmed: 22307137
Gynecol Oncol. 2016 Feb;140(2):204-9
pubmed: 26616225
J Clin Oncol. 2015 Jan 20;33(3):244-50
pubmed: 25366685
Cancer Treat Res Commun. 2018;14:7-12
pubmed: 30104007
J Natl Cancer Inst. 2016 Feb 04;108(7):
pubmed: 26848151
J Clin Invest. 2017 Jun 1;127(6):2392-2406
pubmed: 28481221
Oncotarget. 2015 Dec 22;6(41):43978-91
pubmed: 26539646
Cancer Chemother Pharmacol. 2017 Sep;80(3):631-643
pubmed: 28770300
Clin Cancer Res. 2017 Aug 1;23(15):4095-4106
pubmed: 28264872
Cancer Sci. 2017 Sep;108(9):1834-1842
pubmed: 28665051
Clin Cancer Res. 2018 Oct 15;24(20):5143-5152
pubmed: 29945991
Lancet Oncol. 2017 Jan;18(1):75-87
pubmed: 27908594
Gynecol Oncol. 2017 Mar;144(3):486-490
pubmed: 28109627
Clin Cancer Res. 2019 May 1;25(9):2717-2724
pubmed: 30563931
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Gynecol Oncol. 2015 Jun;137(3):386-91
pubmed: 25818403
Nature. 2001 May 17;411(6835):366-74
pubmed: 11357144
Nat Rev Cancer. 2004 Oct;4(10):814-9
pubmed: 15510162
Diagnostics (Basel). 2019 Aug 01;9(3):
pubmed: 31374917
Clin Cancer Res. 2018 Feb 15;24(4):744-752
pubmed: 29138343
Nat Rev Cancer. 2016 Feb;16(2):110-20
pubmed: 26775620
Clin Cancer Res. 2015 Apr 1;21(7):1574-82
pubmed: 25589624
DNA Repair (Amst). 2014 May;17:2-8
pubmed: 24582502
Cancer Discov. 2017 Jun;7(6):620-629
pubmed: 28242752
Lancet Oncol. 2014 Jul;15(8):852-61
pubmed: 24882434
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Nat Struct Mol Biol. 2014 Apr;21(4):366-74
pubmed: 24658350
Nucleic Acids Res. 2014 Jul;42(12):7762-75
pubmed: 24928857
Lancet Oncol. 2017 Sep;18(9):1274-1284
pubmed: 28754483
Science. 2003 Oct 24;302(5645):643-6
pubmed: 14576434
N Engl J Med. 2003 May 8;348(19):1917-9
pubmed: 12736286
Front Oncol. 2014 Dec 19;4:368
pubmed: 25566506
Clin Cancer Res. 2016 Jul 1;22(13):3227-37
pubmed: 26842236
Mol Cell. 2015 Jun 18;58(6):902-10
pubmed: 26091339
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
Cancer Sci. 2017 Nov;108(11):2213-2220
pubmed: 28837250
Clin Cancer Res. 2017 Nov 1;23(21):6400-6410
pubmed: 28790114
Nature. 1993 Apr 22;362(6422):709-15
pubmed: 8469282